no title
Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/..
Adjuvant and neoadjuvant therapy of early breast cancer reduces the risk of relapse and breast cancer mortality. Treatment modalities include chemotherapy, endocrine therapy, human epidermal growth factor receptor 2-targeted agents, bisphosphonates, immunotherapy, cyclin-dependent kinase inhibitors 4/6- and poly-ADP-ribose polymerase inhibitors. All cases are reviewed at multidisciplinary breast cancer tumour boards. An individualized risk stratification model is applied in this review to optimize the risk-benefit ratio for each patient, and shared decision-making is an integrated part of (neo)adjuvant therapy. Danish guidelines for breast cancer treatment are available at Danish Breast Cancer Cooperative Group's home page.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:186 |
|---|---|
| Enthalten in: |
Ugeskrift for laeger - 186(2024), 12 vom: 18. März |
| Sprache: |
Dänisch |
|---|
| Weiterer Titel: |
Medical treatment of early breast cancer |
|---|
| Beteiligte Personen: |
Bjerre, Christina Annette [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 28.03.2024 Date Revised 01.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.61409/V02230095 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370234227 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370234227 | ||
| 003 | DE-627 | ||
| 005 | 20240401232901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240328s2024 xx |||||o 00| ||dan c | ||
| 024 | 7 | |a 10.61409/V02230095 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM370234227 | ||
| 035 | |a (NLM)38533871 | ||
| 035 | |a (PII)V02230095 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a dan | ||
| 100 | 1 | |a Bjerre, Christina Annette |e verfasserin |4 aut | |
| 246 | 3 | 3 | |a Medical treatment of early breast cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2024 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/. | ||
| 520 | |a Adjuvant and neoadjuvant therapy of early breast cancer reduces the risk of relapse and breast cancer mortality. Treatment modalities include chemotherapy, endocrine therapy, human epidermal growth factor receptor 2-targeted agents, bisphosphonates, immunotherapy, cyclin-dependent kinase inhibitors 4/6- and poly-ADP-ribose polymerase inhibitors. All cases are reviewed at multidisciplinary breast cancer tumour boards. An individualized risk stratification model is applied in this review to optimize the risk-benefit ratio for each patient, and shared decision-making is an integrated part of (neo)adjuvant therapy. Danish guidelines for breast cancer treatment are available at Danish Breast Cancer Cooperative Group's home page | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Rønlev, Jeanette Dupont |e verfasserin |4 aut | |
| 700 | 1 | |a Knop, Ann Søegaard |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ugeskrift for laeger |d 1945 |g 186(2024), 12 vom: 18. März |w (DE-627)NLM000011185 |x 1603-6824 |7 nnns |
| 773 | 1 | 8 | |g volume:186 |g year:2024 |g number:12 |g day:18 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.61409/V02230095 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 186 |j 2024 |e 12 |b 18 |c 03 | ||